{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:50:24Z","timestamp":1768589424573,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015831","name":"Radius Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00198-024-07070-z","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:01:45Z","timestamp":1713924105000},"page":"1407-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study"],"prefix":"10.1007","volume":"35","author":[{"given":"Deborah T.","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-4718","authenticated-orcid":false,"given":"Chad","family":"Deal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahshid","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-4955","authenticated-orcid":false,"given":"Abigail","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-3917","authenticated-orcid":false,"given":"Leny","family":"Pearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-7327","authenticated-orcid":false,"given":"John","family":"Caminis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-9836","authenticated-orcid":false,"given":"Yamei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-2677","authenticated-orcid":false,"given":"Setareh A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Kernaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"10","key":"7070_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"7070_CR2","unstructured":"Bone Health and Osteoporosis Foundation. 54 Million Americans Affected by Osteoporosis and Low Bone Mass. June 2, 2014. Accessed November 21, 2022. https:\/\/www.bonehealthandosteoporosis.org\/2014\/06\/02\/54-million-americans-affected-by-osteoporosis-and-low-bone-mass\/"},{"issue":"1","key":"7070_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/21556660.2019.1677674","volume":"8","author":"T Gold","year":"2019","unstructured":"Gold T, Williams SA, Weiss RJ, Wang Y, Watkins C, Carroll J, Middleton C, Silverman S (2019) Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey. J Drug Assess 8(1):175\u2013183. https:\/\/doi.org\/10.1080\/21556660.2019.1677674","journal-title":"J Drug Assess"},{"key":"7070_CR4","unstructured":"Hansen D, Pelizzari P, Pyenson B. Medicare cost of osteoporotic fractures - 2021 updated report. The clinical and cost burden of fractures associated with osteoporosis. Milliman Research Report. March 2021. Accessed July 19, 2023. https:\/\/www.milliman.com\/en\/insight\/-\/media\/milliman\/pdfs\/2021-articles\/3-30-21-Medicare-Cost-Osteoporotic-Fractures.ashx"},{"issue":"7","key":"7070_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","volume":"55","author":"SA Williams","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55(7):821\u2013829. https:\/\/doi.org\/10.1177\/1060028020970518","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"7070_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/gl-2020-0524suppl","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa WNB (2020) American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/gl-2020-0524suppl","journal-title":"Endocr Pract"},{"issue":"2","key":"7070_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ecl.2021.03.009","volume":"50","author":"RM Arceo-Mendoza","year":"2021","unstructured":"Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am 50(2):167\u2013178","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"7070_CR8","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.5435\/JAAOS-D-22-00476","volume":"31","author":"BW Diffenderfer","year":"2023","unstructured":"Diffenderfer BW, Wang Y, Pearman L, Pyrih N, Williams SA (2023) Real-world management of patients with osteoporosis at very high risk for fracture. J Am Acad Orthop Surg 31(6):e327\u2013e335","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"7070_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00198-015-3388-3","volume":"27","author":"A Modi","year":"2016","unstructured":"Modi A, Sen S, Adachi JD, Adami S, Cortet B, Cooper AL, Geusens P, Mellstr\u00f6m D, Weaver J, van den Burgh JP, Nguyen AM, Sajjan S, MUSIC-OS Study Group (2016) Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27(3):1227\u20131238. https:\/\/doi.org\/10.1007\/s00198-015-3388-3","journal-title":"Osteoporos Int"},{"issue":"2","key":"7070_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-011-1620-3","volume":"23","author":"E Barrett-Connor","year":"2012","unstructured":"Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US\u2122. Osteoporos Int 23(2):733\u2013741. https:\/\/doi.org\/10.1007\/s00198-011-1620-3","journal-title":"Osteoporos Int"},{"issue":"2 Suppl","key":"7070_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstr\u00f6m F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3-13. https:\/\/doi.org\/10.1016\/j.amjmed.2008.12.002","journal-title":"Am J Med"},{"issue":"1","key":"7070_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11657-022-01075-z","volume":"17","author":"C Beaudart","year":"2022","unstructured":"Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M (2022) A qualitative study to assess US patient preferences between new transdermal system and injectable anabolic therapies for osteoporosis treatment. Arch Osteoporos 17(1):57. https:\/\/doi.org\/10.1007\/s11657-022-01075-z","journal-title":"Arch Osteoporos"},{"issue":"1","key":"7070_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/21556660.2019.1579728","volume":"8","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Leader D, Weiss R, Williams SA (2019) Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. J Drug Assess 8(1):25\u201331. https:\/\/doi.org\/10.1080\/21556660.2019.1579728","journal-title":"J Drug Assess"},{"key":"7070_CR14","unstructured":"Tymlos. Prescribing information. Radius Health Inc; 2017. Revised June 2023. Accessed November 16, 2023. https:\/\/radiuspharm.com\/wp-content\/uploads\/tymlos\/tymlos-prescribing-information.pdf"},{"issue":"7","key":"7070_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu M-Y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"issue":"8","key":"7070_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33(8):1703\u20131714. https:\/\/doi.org\/10.1007\/s00198-022-06413-y","journal-title":"Osteoporos Int"},{"issue":"3","key":"7070_CR17","doi-asserted-by":"publisher","first-page":"e10457","DOI":"10.1002\/jbm4.10457","volume":"5","author":"DT Gold","year":"2021","unstructured":"Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA (2021) Abaloparatide real-world patient experience study. JBMR Plus 5(3):e10457. https:\/\/doi.org\/10.1002\/jbm4.10457","journal-title":"JBMR Plus"},{"issue":"1","key":"7070_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-0170316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22. https:\/\/doi.org\/10.1007\/s11657-0170316-5","journal-title":"Arch Osteoporos"},{"issue":"9","key":"7070_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.18553\/jmcp.2015.21.9.824","volume":"21","author":"L-I Cheng","year":"2015","unstructured":"Cheng L-I, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS (2015) Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm 21(9):824\u2013833a. https:\/\/doi.org\/10.18553\/jmcp.2015.21.9.824","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"7070_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.18553\/jmcp.2011.17.1.25","volume":"17","author":"R Halpern","year":"2011","unstructured":"Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25\u201339. https:\/\/doi.org\/10.18553\/jmcp.2011.17.1.25","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"7070_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571\u2013581. https:\/\/doi.org\/10.1016\/j.jval.2010.11.010","journal-title":"Value Health"},{"issue":"11","key":"7070_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.18553\/jmcp.2017.17054","volume":"23","author":"A Keshishian","year":"2017","unstructured":"Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare population. J Manag Care Spec Pharm 23(11):1178\u20131190. https:\/\/doi.org\/10.18553\/jmcp.2017.17054","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"7070_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1185\/03007995.2015.1016605","volume":"31","author":"A Modi","year":"2015","unstructured":"Modi A, Siris ES, Tang J, Sen S (2015) Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin 31(4):757\u2013765. https:\/\/doi.org\/10.1185\/03007995.2015.1016605","journal-title":"Curr Med Res Opin"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07070-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T20:04:27Z","timestamp":1722024267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07070-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7070"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07070-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DTG is a consultant for Radius Health, Inc. (Radius). TBeckett is a former speaker for Radius, Amgen, and Eli Lilly and an investigator for Radius, and her institution received funding to conduct the study reported here. CD has participated in advisory boards and is a speaker for Amgen, Eli Lilly, and Radius. ALJ is a speaker for Amgen. MM has no conflicts of interest to disclose. AM and TBailey are employees of Adelphi Real World, Bollington, UK, and are paid consultants of Radius. LP and YW are employees of Radius. JC and SAW are former employees of Radius. SAW is currently a consultant for Radius. JMK is a consultant for Radius and Alexion, a speaker for Alexion, Amgen, and Radius, and has participated in advisory boards for Alexion, Amgen, and Radius.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}